According to Goldstein Research, global oncology biosimilars market is expected to grow at 25.0% CAGR over the forecast period 2017-2025. The factors such as growth in a number of cancer patients, a rising number of hospitals, and a large number of oncology biosimilars in the pipeline are driving the growth of the Oncology Biosimilars Market. The expansion of the market is positively impacted by expanding the R&D of biomarkers such as in Cancer treatment. The Cancer Biomarker Market is still at the nascent stage and has not yet received approval from FDA, but tremendous R&D will lead to definite results in near future. Further, oncology biosimilars have initiated the trend of ‘precision medicine’ wherein tailored treatment is provided to the individual patient. Hence, the Biosimilar Market is propelling at high growth rate, such that in 2017 European Medicines Agency (EMA) had approved 16 biosimilars. Whereas, European Commission (EC), had approved 19 biosimilars for therapeutic medicines and in total 40 biosimilars across multiple categories till March 2018.
Browse Full Report: https://www.goldsteinresearch.com/report/cancer-biosimilars-market-oncology-industry
Market Segmentation
On the basis of our in-depth analysis, Global Oncology BiosimilarsMarket can be segmented as follows:
Based on Product Type
- Monoclonal Antibody
- Immunomodulators
- Others
Based on Application
- Cancer Treatment Drugs
- Supportive Care Drugs
Based on Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region
- North America Oncology Biosimilars Market Analysis, 2017-2025
- Europe Oncology Biosimilars Market Analysis, 2017-2025
- Middle East And Africa Oncology Biosimilars Market Analysis, 2017-2025
- Latin America Oncology Biosimilars Market Analysis, 2017-2025
- Asia Pacific Oncology Biosimilars Market Analysis, 2017-2025
“Global Oncology Biosimilars Market Outlook 2025” includes a comprehensive overview of the global oncology biosimilars market. On the basis of our in-depth analysis, the market can be segmented in terms of market segmentation by product type, application, distribution channel and geography.
Download Exclusive Sample Report:
The Global Oncology Biosimilars Market Report highlights the competitive outlook of major global players that includes business strategies, product portfolio, revenue distribution, financial analysis, R&D activities, and investments. The comprehensive analysis of the oncology biosimilars market report is drafted as per the clients to help them in assessing their business strategies in a competitive environment.
Key players discussed in the report are:
Amgen, BoehringerIngelheim, Novartis, Biocon, Roche and many more.
Further, Global Oncology Biosimilars Market Report encompasses the key factors driving the growth of the market, opportunities in the market and the factors posing threats & challenges to the market. The oncology biosimilars market outlook also comprises the market dynamics, risk analysis, SWOT analysis, USP analysis, BPS Analysis & market attractiveness. Report further also includes the expert analysis and remarks showcasing the complete overview of the market based on intensive analysis of political, economic, social, technological, environmental & legal factors of each region in the market.
Global Oncology Biosimilars Market is driving on the basis of advancement in branches of healthcare mentioned below:
Biopharmaceuticals Market
Biopharmaceuticals & biomedicine deals with the research and development of drugs (biologics) partially or completely using biological compounds. The year 2017 has witnessed huge growth in the Biopharmaceutical Market Biomedicines are increasingly penetrating the market as the drug manufacturers and other pharmaceutical companies are inclining towards R&D of biomedicine.
Nano Chemotherapy Market
According to Goldstein Research, Nano chemotherapy market is expected to reach USD 3.5 billion by 2024, growing at a CAGR of 7.45% over the forecast period 2016-2024. The fact that the presence of bioavailability-improved Nanoscale particles and molecules in order to make drug delivery focuses on maximizing bioavailability both at specific places in the body and over a period of time is driving the growth of the Nano chemotherapy Industry
Chemotherapy Market
The global Chemotherapy Market is expected to reach a market size of USD 128.7 billion by 2025, growing at 63.0% CAGR over the forecast period 2017-2025. Chemotherapy is a cancer-curing treatment which is delivered either through site-specific or through the bloodstream. With the technological advancement and continuous R&D new cancer treatment drugs, devices and procedures are entering the Chemotherapy market.
Melanoma Scanner Market
The Melanoma Scanner Market size is set to reach USD 850 million by 2025, at a CAGR of 7.6% over the forecast period. High investment by skin cancer diagnostic & therapeutic companies and an increasing number of pipeline products for cancer diagnosis under clinical trials are the key factors which are driving the growth of the market of melanoma scanners. Handheld melanoma scanner dominated the APAC Melanoma Scanner Market and accounted for the market share of 63.1% in 2017 of total melanoma scanner market attributed to the hand-held device are easy to learn and use, and it rapidly provides accurate images of the melanin, blood, and collagen below the mole or lesion. The Handheld Melanoma Scanner Market size is set to reach USD 650 million by 2025, at a CAGR of 8.12% over the forecast years.
Cancer Services Market
The global cancer services market is projected to grow at a CAGR of 15.7% whereas global cancer therapy market is anticipated to grow at CAGR of 16.7% during the forecast period. Asia-Pacific cancer services market valued USD 15.3 billion in 2016. As per WHO, LA and MEA together accounted for 11.2% of total deaths caused by cancer.
Contact for more Info:
Steve Blade
(Global Sales Head)
USA: + 1-646-568-7747
Canada: +1-437-886-1181
UK: +44-203-318-6627
Comments
Post a Comment